Impact BioMedical Inc.
IBO
$0.91
-$0.02-2.15%
| Weiss Ratings | IBO - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | D | |||
| Rating Factors | IBO - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Fair | |||
| Solvency Index | Fair | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | IBO - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | IBO - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -40.91% | |||
| 30-Day Total Return | -48.56% | |||
| 60-Day Total Return | -58.26% | |||
| 90-Day Total Return | -56.46% | |||
| Year to Date Total Return | -40.91% | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -71.38% | |||
| 52-Week Low % Change | 11.83% | |||
| Price | IBO - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $3.25 | |||
| 52-Week Low Price | $0.83 | |||
| 52-Week Low Price (Date) | Mar 07, 2025 | |||
| 52-Week High Price (Date) | Nov 18, 2024 | |||
| Valuation | IBO - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 10.70M | |||
| Enterprise Value | 19.10M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.18 | |||
| Earnings Per Share Growth | 81.58% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.34 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.91 | |||
| Enterprise Value/EBITDA (TTM) | -5.22 | |||
| Enterprise Value/EBIT | -5.21 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | IBO - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 72.00M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | IBO - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 585-325-3610 | |||
| Address | 1400 Broadfield Blvd. Houston, TX 77084 | |||
| Website | www.impactbiomedinc.com | |||
| Country | United States | |||
| Year Founded | 2018 | |||
| Profitability | IBO - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | IBO - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -4.99% | |||
| Return on Equity | 3.43% | |||
| Income Statement | IBO - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -3.66M | |||
| EBIT (TTM) | -3.66M | |||
| Net Income (TTM) | 1.16M | |||
| Net Income Avl. to Common (TTM) | 1.16M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 460.32% | |||
| EPS Diluted (TTM) | -0.18 | |||
| EPS Diluted Growth (Q YOY) | 400.00% | |||
| Balance Sheet | IBO - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.67M | |||
| Cash Per Share (Q) | $0.04 | |||
| Total Current Assets (Q) | 3.18M | |||
| Total Preferred Equity (Q) | 0.06 | |||
| Total Equity (Q) | 34.35M | |||
| Current Ratio (Q) | 2.790 | |||
| Book Value Per Share (Q) | $2.72 | |||
| Total Assets (Q) | 46.70M | |||
| Total Current Liabilities (Q) | 1.14M | |||
| Total Debt (Q) | 8.01M | |||
| Total Liabilities (Q) | 12.34M | |||
| Total Common Equity (Q) | 31.29M | |||
| Cash Flow | IBO - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 3.00K | |||
| Cash from Financing (TTM) | 5.56M | |||
| Net Change in Cash (TTM) | 2.47M | |||
| Levered Free Cash Flow (TTM) | -1.33M | |||
| Cash from Operations (TTM) | -3.10M | |||
